SCHEMBL30278876

SCHEMBL30278876

C[C@@H](O)[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 20/20 0.60
▸ SCTR P47872 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29554395 0.95 GLP1R (0.63) GLP1RSCTR
SCHEMBL30637757 0.93 GLP1R (0.53) GLP1RSCTR
SCHEMBL30091379 0.93 GLP1R (0.58) GLP1RSCTR
SCHEMBL30091176 0.93 GLP1R (0.58) GLP1RSCTR
SCHEMBL29375282 0.93 GLP1R (0.56) GLP1RSCTR
SCHEMBL30978208 0.93 GLP1R (0.65) GLP1RSCTR
SCHEMBL29663731 0.93 GLP1R (0.66) GLP1RSCTR
SCHEMBL30091171 0.93 GLP1R (0.58) GLP1RSCTR
SCHEMBL30091352 0.91 GLP1R (0.57) GLP1RSCTR
SCHEMBL30091122 0.91 GLP1R (0.56) GLP1RSCTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230220035-A1 LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST DONG-A ST CO., LTD. (KR) 2023-07-13 — — US claimed
US-20230220035-A1 LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST DONG-A ST CO., LTD. (KR) 2023-07-13 — — US disclosed
EP-4144757-A1 LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST Dong-A ST Co., Ltd. (KR) 2023-03-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230220035-A1 LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST GLP1R, GIPR, GCGR GLP1R 1/4885SCTR 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback